Eli Lilly Leverages AI to Transform Drug Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 15 2026
0mins
Should l Buy LLY?
Source: Fool
- AI Platform Launch: Eli Lilly launched the TuneLab platform in September last year, allowing other drugmakers digital access to proprietary data on drug molecule performance, which saves significant time and money, enabling companies to focus on their best research projects.
- Major Investment Partnership: Eli Lilly partnered with Nvidia, committing $1 billion to build a supercomputer aimed at deepening disease understanding and advancing drug development, marking a significant step in the company's AI drug development efforts.
- Huge Market Potential: According to Straits Research, the AI-powered drug discovery industry is expected to grow at an annual rate of 30% through 2034, reaching over $20 billion, providing Eli Lilly with substantial future revenue opportunities.
- Increased Collaboration Opportunities: By owning a powerful drug development platform, Eli Lilly can not only optimize its own research but also establish partnerships with smaller pharmaceutical companies, helping them bring new drugs to market and enhancing its competitive edge.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 927.060
Low
950.00
Averages
1192
High
1500
Current: 927.060
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's New Drug Approval May Boost Stock Recovery
- FDA Drug Approval: On April 1, Eli Lilly announced that the FDA approved its oral GLP-1 weight-loss drug Foundayo, marking a significant milestone that strengthens its leadership in the rapidly growing weight-loss market and is expected to attract more patients who prefer oral medications.
- Competitive Advantage: Unlike its competitor oral Wegovy, Foundayo can be taken without food or water restrictions and costs as low as $149 per month, significantly reducing the financial burden on patients, which could expand market share and boost sales.
- New Drug Potential: Although Foundayo's efficacy is lower than Zepbound, its convenience and cost advantages are likely to garner significant attention in the weight-loss drug market, while Eli Lilly is also developing additional weight-loss medications to further penetrate the market.
- Long-term Investment Value: Eli Lilly is expanding its product line through licensing deals and acquisitions, heavily investing in artificial intelligence for innovation, and improving its margins in recent years, making its stock attractive for long-term investors despite a 13% decline this year.
See More
New Tax Year Brings Economic Challenges for UK Households
- Tax Policy Impact: The start of the 2026-27 tax year in the UK sees frozen tax thresholds and allowances, pushing many workers into higher tax brackets due to wage increases, thereby increasing household tax burdens and reducing disposable income.
- Rising Compliance Costs for SMEs: The new 'Making Tax Digital' rules require 860,000 sole traders and landlords to report income and expenses quarterly to HMRC, which is expected to raise compliance costs and add financial strain on small businesses.
- Increased Cost of Living: Households are facing rising living costs, particularly with water bills and council tax increasing, with an average council tax hike of 4.99%, exacerbating financial pressures on families amid rising energy prices due to the Middle East conflict.
- Insufficient Government Support: Although benefit payments have increased, the overall rise in living costs indicates that the government's fiscal policies have failed to alleviate economic pressures on households, potentially leading to growing dissatisfaction with the current administration.
See More
AC Immune Revises Collaboration Agreement with Eli Lilly
- Collaboration Agreement Revision: AC Immune has amended its collaboration agreement with Eli Lilly, which will pay 10 million Swiss francs ($12.5 million) as an upfront payment, demonstrating confidence in AC Immune's development of treatments for Alzheimer's and other neurodegenerative diseases.
- Significant Potential Revenue: If AC Immune successfully develops a drug and meets clinical, regulatory, and commercial milestones, total payments could exceed 1.7 billion Swiss francs ($2.1 billion), significantly enhancing the company's financial position and market standing.
- Clinical Trial Progress: CEO Andrea Pfeifer indicated that the company expects to initiate Investigational New Drug (IND)-enabling studies imminently, marking a new stage in its development that could accelerate the path to market for new therapies.
- Positive Market Reaction: Following this favorable collaboration news, AC Immune's stock surged nearly 15% on Tuesday, reflecting investor optimism about the company's future prospects and increasing its visibility in the biotech sector.
See More
The 'Diabesity' Market Is Poised for Rapid Growth: Key Catalysts for Lilly and Novo Stocks.
Weight-loss Drugs in Focus: The spotlight is on weight-loss drugs, particularly GLP-1 medications like Wegovy and Zepbound, as they gain popularity.
Market Competition: Eli Lilly and Novo Nordisk are key players in the emerging "diabesity" market, indicating a competitive landscape ahead.
See More
Eli Lilly's New Weight-Loss Drug Gains Major Approval
- New Drug Approval: Eli Lilly's new weight-loss treatment has received major approval, expected to generate billions in revenue, further solidifying its leadership position in the pharmaceutical industry.
- Market Potential: The demand for this weight-loss drug is strong, particularly against the backdrop of rising obesity rates, which could attract a large consumer base and drive sales growth.
- Stock Price Reaction: On the afternoon of April 3, 2026, Eli Lilly's stock price rose by 0.34%, reflecting the market's positive response to the drug approval and significantly enhancing investor expectations for future earnings.
- Strategic Implications: This approval not only enhances Eli Lilly's product portfolio but may also enable the company to capture a larger share of the competitive weight-loss drug market, bolstering its long-term growth potential.
See More
AC Immune Amends Collaboration Agreement with Eli Lilly
- Agreement Amendment: AC Immune has amended its 2018 collaboration agreement with Eli Lilly, continuing to cover R&D efforts for the new class of neurology therapies, Morphomer Tau, indicating ongoing partnership in neurodegenerative diseases like Alzheimer's.
- Increased Funding: The amendment allows AC Immune to receive an upfront payment of CHF 10 million and a milestone payment upon the start of Phase 1 dosing, providing crucial financial support for its R&D efforts and enhancing its financial stability.
- R&D Timeline: AC Immune plans to initiate investigational new drug (IND)-enabling studies in H1 2026, establishing a timeline that will bolster the company's competitive position in the neurodegenerative disease treatment market.
- Positive Market Reaction: Following the agreement amendment, AC Immune's stock price rose, reflecting investor optimism regarding the company's future R&D potential, which may attract more investor interest in its innovative capabilities within the biotech sector.
See More
Eli Lilly's New Drug Approval May Boost Stock Recovery
- FDA Drug Approval: On April 1, Eli Lilly announced that the FDA approved its oral GLP-1 weight-loss drug Foundayo, marking a significant milestone that strengthens its leadership in the rapidly growing weight-loss market and is expected to attract more patients who prefer oral medications.
- Competitive Advantage: Unlike its competitor oral Wegovy, Foundayo can be taken without food or water restrictions and costs as low as $149 per month, significantly reducing the financial burden on patients, which could expand market share and boost sales.
- New Drug Potential: Although Foundayo's efficacy is lower than Zepbound, its convenience and cost advantages are likely to garner significant attention in the weight-loss drug market, while Eli Lilly is also developing additional weight-loss medications to further penetrate the market.
- Long-term Investment Value: Eli Lilly is expanding its product line through licensing deals and acquisitions, heavily investing in artificial intelligence for innovation, and improving its margins in recent years, making its stock attractive for long-term investors despite a 13% decline this year.
See More
New Tax Year Brings Economic Challenges for UK Households
- Tax Policy Impact: The start of the 2026-27 tax year in the UK sees frozen tax thresholds and allowances, pushing many workers into higher tax brackets due to wage increases, thereby increasing household tax burdens and reducing disposable income.
- Rising Compliance Costs for SMEs: The new 'Making Tax Digital' rules require 860,000 sole traders and landlords to report income and expenses quarterly to HMRC, which is expected to raise compliance costs and add financial strain on small businesses.
- Increased Cost of Living: Households are facing rising living costs, particularly with water bills and council tax increasing, with an average council tax hike of 4.99%, exacerbating financial pressures on families amid rising energy prices due to the Middle East conflict.
- Insufficient Government Support: Although benefit payments have increased, the overall rise in living costs indicates that the government's fiscal policies have failed to alleviate economic pressures on households, potentially leading to growing dissatisfaction with the current administration.
See More
AC Immune Revises Collaboration Agreement with Eli Lilly
- Collaboration Agreement Revision: AC Immune has amended its collaboration agreement with Eli Lilly, which will pay 10 million Swiss francs ($12.5 million) as an upfront payment, demonstrating confidence in AC Immune's development of treatments for Alzheimer's and other neurodegenerative diseases.
- Significant Potential Revenue: If AC Immune successfully develops a drug and meets clinical, regulatory, and commercial milestones, total payments could exceed 1.7 billion Swiss francs ($2.1 billion), significantly enhancing the company's financial position and market standing.
- Clinical Trial Progress: CEO Andrea Pfeifer indicated that the company expects to initiate Investigational New Drug (IND)-enabling studies imminently, marking a new stage in its development that could accelerate the path to market for new therapies.
- Positive Market Reaction: Following this favorable collaboration news, AC Immune's stock surged nearly 15% on Tuesday, reflecting investor optimism about the company's future prospects and increasing its visibility in the biotech sector.
See More
The 'Diabesity' Market Is Poised for Rapid Growth: Key Catalysts for Lilly and Novo Stocks.
Weight-loss Drugs in Focus: The spotlight is on weight-loss drugs, particularly GLP-1 medications like Wegovy and Zepbound, as they gain popularity.
Market Competition: Eli Lilly and Novo Nordisk are key players in the emerging "diabesity" market, indicating a competitive landscape ahead.
See More
Eli Lilly's New Weight-Loss Drug Gains Major Approval
- New Drug Approval: Eli Lilly's new weight-loss treatment has received major approval, expected to generate billions in revenue, further solidifying its leadership position in the pharmaceutical industry.
- Market Potential: The demand for this weight-loss drug is strong, particularly against the backdrop of rising obesity rates, which could attract a large consumer base and drive sales growth.
- Stock Price Reaction: On the afternoon of April 3, 2026, Eli Lilly's stock price rose by 0.34%, reflecting the market's positive response to the drug approval and significantly enhancing investor expectations for future earnings.
- Strategic Implications: This approval not only enhances Eli Lilly's product portfolio but may also enable the company to capture a larger share of the competitive weight-loss drug market, bolstering its long-term growth potential.
See More
AC Immune Amends Collaboration Agreement with Eli Lilly
- Agreement Amendment: AC Immune has amended its 2018 collaboration agreement with Eli Lilly, continuing to cover R&D efforts for the new class of neurology therapies, Morphomer Tau, indicating ongoing partnership in neurodegenerative diseases like Alzheimer's.
- Increased Funding: The amendment allows AC Immune to receive an upfront payment of CHF 10 million and a milestone payment upon the start of Phase 1 dosing, providing crucial financial support for its R&D efforts and enhancing its financial stability.
- R&D Timeline: AC Immune plans to initiate investigational new drug (IND)-enabling studies in H1 2026, establishing a timeline that will bolster the company's competitive position in the neurodegenerative disease treatment market.
- Positive Market Reaction: Following the agreement amendment, AC Immune's stock price rose, reflecting investor optimism regarding the company's future R&D potential, which may attract more investor interest in its innovative capabilities within the biotech sector.
See More
